JNJ Stock Recent News

Dividend King stocks with over a half century of dividend increases can often fall into a rut over time.

When seeking companies for your retirement portfolio, I suggest focusing on companies with significant competitive advantages, a strong balance sheet and the capacity to pay sustainable dividends. I am convinced that each of these selected five companies is a particularly attractive risk-reward choice, ensuring capital preservation and elevated risk-adjusted returns. While one company offers a particularly attractive dividend yield [FWD] of 5.77%, another one offers strong dividend growth potential (reflected in its 10-Year dividend growth rate [CAGR] of 17.57%).

Investing in stocks comes with risks. There's no way around that fact.

Two recent catalysts, one technical and one fundamental, have promoted me to adjust my rating on JNJ to a HOLD from my earlier buy rating. Technical trading patterns signal that JNJ is entering a consolidation phase with no clear directional momentum in the near term. In the meantime, JNJ's valuation ratios have expanded, narrowing the discount compared to historical averages and shifting its return/risk profile.

A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64 billion after a jury found it liable in a whistleblower lawsuit for illegally promoting the HIV drugs Prezista and Intelence.

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Fears of a looming recession seem to be rising, partly fueled by President Donald Trump's macroeconomic policies. While it's impossible to predict whether an economic downturn is indeed coming, it's not a bad idea for investors to purchase shares of companies that are likely to perform relatively well in case it does happen.

The Dividend Income Accelerator Portfolio focuses on financially healthy companies with strong balance sheets, aiming to generate sustainable dividend income and reduce portfolio volatility. Recent additions like Canadian Natural Resources and NextEra Energy enhance dividend growth potential and diversify sector allocation, reducing Financials Sector concentration. The portfolio boasts a Weighted Average Dividend Yield [FWD] of 3.98% and a 5-Year Weighted Average Dividend Growth Rate [CAGR] of 7.82%, ensuring attractive income and growth.

Healthcare headwinds have @Theotrade's Don Kaufman leaning bearish on Johnson & Johnson (JNJ) while staying bullish in GE Aerospace (GE) despite hitting 18-year highs today. He offers options trades in those companies alongside an earnings play for Lululemon (LULU).

Median overall survival not yet reached with projected improvement of more than one year versus osimertinib RARITAN, N.J. , March 26, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results for the gold standard endpoint in cancer treatment of overall survival (OS) from the Phase 3 MARIPOSA study.